Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5179 for:    ROYAL 1
Previous Study | Return to List | Next Study

A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02634151
Recruitment Status : Completed
First Posted : December 17, 2015
Results First Posted : June 25, 2020
Last Update Posted : June 25, 2020
Sponsor:
Information provided by (Responsible Party):
NeuroBo Pharmaceuticals Inc.

Brief Summary:
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100 mg/dL. Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.

Condition or disease Intervention/treatment Phase
Hypercholesteremia Drug: Gemcabene Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
Study Start Date : November 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : August 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
Drug: Placebo
Three placebo tablets administered orally once daily for 12 weeks.

Experimental: Gemcabene 600 mg
Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
Drug: Gemcabene
Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.




Primary Outcome Measures :
  1. Percent Change From Baseline in LDL-C at Week 12 [ Time Frame: Baseline, Week 12 ]

Secondary Outcome Measures :
  1. Percent Change From Baseline in LDL-C by Statin Intensity Stratum [ Time Frame: Baseline, Week 12 ]
    The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity & moderate intensity based on their statin doses.

  2. Change From Baseline in LDL-C [ Time Frame: Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12 ]
  3. Percent Change From Baseline in LDL-C [ Time Frame: Baseline, average of weeks 8 and 12 ]
  4. Percent Change From Baseline in Non-HDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  5. Change From Baseline in Non-HDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  6. Percent Change From Baseline in TC [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  7. Change From Baseline in TC [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  8. Percent Change From Baseline in TG [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  9. Change From Baseline in TG [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  10. Percent Change From Baseline in VLDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  11. Change From Baseline in VLDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  12. Percent Change From Baseline in HDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  13. Change From Baseline in HDL-C [ Time Frame: Baseline, Weeks 2, 4, 8 and 12 ]
  14. Number of Participants Achieving LDL-C Reduction of ≥10% [ Time Frame: Weeks 4, 8 and 12 ]
  15. Number of Participants Achieving LDL-C Reduction of ≥15% [ Time Frame: Weeks 4, 8 and 12 ]
  16. Number of Participants Achieving LDL-C Reduction of ≥20% [ Time Frame: Weeks 4, 8 and 12 ]
  17. Number of Participants Achieving an LDL-C Value <100 mg/dL (2.59 mmol/L) [ Time Frame: Weeks 4, 8 and 12 ]
  18. Percent Change From Baseline in Apolipoprotein B [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  19. Change From Baseline in Apolipoprotein B [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  20. Percent Change From Baseline in Apolipoprotein A-I [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  21. Change From Baseline in Apolipoprotein A-I [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  22. Percent Change From Baseline in Apolipoprotein A-II [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  23. Change From Baseline in Apolipoprotein A-II [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  24. Percent Change From Baseline in Apolipoprotein C-II [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  25. Change From Baseline in Apolipoprotein C-II [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  26. Percent Change From Baseline in Apolipoprotein C-III [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  27. Change From Baseline in Apolipoprotein C-III [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  28. Percent Change From Baseline in Apolipoprotein E [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  29. Change From Baseline in Apolipoprotein E [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  30. Percent Change From Baseline in Lipoprotein(a) [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  31. Change From Baseline in Lipoprotein(a) [ Time Frame: Baseline, Weeks 4, 8 and 12 ]
  32. Percent Change From Baseline in High-sensitivity C-reactive Protein [ Time Frame: Baseline, Week 12 ]
  33. Change From Baseline in High-sensitivity C-reactive Protein [ Time Frame: Baseline, Week 12 ]
  34. Percent Change From Baseline in Fibrinogen [ Time Frame: Baseline, Week 12 ]
  35. Change From Baseline in Fibrinogen [ Time Frame: Baseline, Week 12 ]
  36. Percent Change From Baseline in Serum Amyloid A [ Time Frame: Baseline, Week 12 ]
  37. Change From Baseline in Serum Amyloid A [ Time Frame: Baseline, Week 12 ]
  38. Percent Change From Baseline in Adiponectin [ Time Frame: Baseline, Week 12 ]
  39. Change From Baseline in Adiponectin [ Time Frame: Baseline, Week 12 ]
  40. Change From Baseline in Framingham Risk Score [ Time Frame: Baseline, Week 12 ]
    Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status. Reported score is a percentage. Change from baseline calculated as mean at week 12 minus mean at baseline. Negative scores indicate less risk of developing cardiovascular disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedures;
  2. Male or female (neither pregnant or lactating) ≥ 18 years of age at the time of consent;
  3. Currently on a stable, low-fat, low-cholesterol diet in combination with allowed statin doses as described in Table 1, with or without ezetimibe 10 mg QD for at least 12 weeks prior to the Screening Visit;
  4. Fasting LDL-C value ≥ 100 mg/dL (2.59 mmol/L) at the Screening Visit;
  5. Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;
  6. Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m2
  7. Subjects with Type 2 diabetes who take anti-hyperglycemic agents must be on a stable regimen for at least 3 months, with no planned changes in medications for the study duration.

Exclusion Criteria

  1. Abnormal liver function test at the Pre-Screening or Screening Visit (AST or ALT) > 2x ULN (upper limit of normal), total bilirubin > 1.5x ULN, or alkaline phosphate > 2x ULN based on appropriate age and gender normal values. Subjects with bilirubin > 1.5x ULN and a history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
  2. Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to the Child-Pugh classification;
  3. Active liver disease (e.g. cirrhosis, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of HIV or AIDS;
  4. Triglyceride value ≥ 500 mg/dL at the Pre-Screening Visit or the Screening Visit;
  5. Moderate to severe renal insufficiency define as an estimated GFR < 60mL/min/1.73m (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or Screening Visit;
  6. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria) confirmed by reflexive urine protein:creatinine ration testing;
  7. Uncontrolled thyroid disease; hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5x ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to Screening;
  8. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (hemoglobin A1c value > 8.5% based on results from the Pre-Screening or Screening Visit, or taking a thiazolidinedione (i.e. pioglitazone or rosiglitazone);
  9. New York Heart Association Class III or IV heart failure;
  10. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit. Subjects with adequately treated stable angina, per Investigator assessment, may be included;
  11. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Day 1 prior to dosing ECG (QTcF > 450 msec for men and > 470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
  12. Uncontrolled hypertension, defined as sitting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg, and confirmed by repeat measurement;
  13. Currently receiving cancer treatments or, in the Investigator's opinion, at risk of relapse for recent cancer;
  14. Inadequate wash-out of a PCSK9 inhibitor (8 weeks prior to the Screening Visit), a fibrate lipid-regulating agent (6 weeks prior to the Screening Visit), niacins (4 weeks prior to the Screening Visit), or other lipid-regulating therapies such as bile acid sequestrants (4 weeks prior to the Screening Visit);
  15. Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid-regulating agent;
  16. Use of any excluded medications or supplements (e.g. potent cytochrome P450 [CYP] 3A4 inhibitors as described in Appendix D;
  17. History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subjects restrictions (see Section 5.6.3);
  18. Previously treated with gemcabene (CI-1027), participation in another clinical study of an investigational agent or device concurrently or within 1 month prior the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit;
  19. Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02634151


Locations
Show Show 24 study locations
Sponsors and Collaborators
NeuroBo Pharmaceuticals Inc.
  Study Documents (Full-Text)

Documents provided by NeuroBo Pharmaceuticals Inc.:
Statistical Analysis Plan  [PDF] July 10, 2017
Study Protocol  [PDF] October 5, 2016

Layout table for additonal information
Responsible Party: NeuroBo Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT02634151    
Other Study ID Numbers: GEM-301
First Posted: December 17, 2015    Key Record Dates
Results First Posted: June 25, 2020
Last Update Posted: June 25, 2020
Last Verified: June 2020
Keywords provided by NeuroBo Pharmaceuticals Inc.:
LDL-C
Lipid Regulator
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases